Undisclosed CDKN2A modulator / Ideaya Biosci - LARVOL DELTA

IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update (PRNewswire) - "Nomination of a development candidate for a potential first-in-class program targeting CDKN2A, the most common co-alteration of MTAP, expected in H2 '26 followed by IND submission to the U.S. FDA in H1 '27....IDE574 (KAT6/7)...targeting to initiate a Phase 1 dose escalation trial in patients with breast, lung, prostate and colorectal cancers Q1 '26."

IND • New P1 trial • Pipeline update • Breast Cancer • Colorectal Cancer • Lung Cancer • Prostate Cancer